Roche Partners with Customers to Redefine the Value of the Laboratory at the AACC 2014 Clinical Lab Expo

Company’s two-booth approach allows customers to see how Roche is partnering with them today and tomorrow

Roche launched its presence at the American Association for Clinical Chemistry (AACC) 2014 Clinical Lab Expo today by unveiling two booths (#1209 and #2009) focused on the unique ways Roche is partnering with customers to redefine the value of the laboratory.

“Our customers tell us every day that they’re looking for a partner to help them maximize the value they deliver in their labs and offices,” said Jack Phillips, president and CEO of Roche
Diagnostics Corporation. “That’s why at this year’s Clinical Lab Expo we’re demonstrating the ways we can work with them to achieve our shared goals through solutions we have on the market today and exciting advances we have planned for tomorrow.”

In booth #1209 Roche exhibited a variety of in vitro diagnostics solutions designed to enhance testing efficiency and provide reliable clinical information from central labs to hospital point of care, clinics and patient homes. Specific product areas included integrated clinical chemistry and immunoassay analyzers, molecular diagnostics platforms, lab automation, immunohistochemistry/in situ hybridization systems, handheld point-of-care testing monitors, and information technology solutions. Booth #1209 was also home to the Roche SmartLab® Theatre, where Expo attendees could hear directly from clinical and industry experts about important updates in automation, change management, personalized healthcare and other key topics.

In booth #2009 Roche unveiled a unique self-guided gallery walk with interactive kiosks,
where attendees could explore Roche’s investments in three main areas: IT Solutions, Peer
Connectivity and Support & Education. In this booth, attendees learnt more about how Roche is transforming information into intelligence.

Roche also continued its commitment to discussing critical industry issues by sponsoring
four workshops in conjunction with the AACC 2014 annual meeting:

1) Building Collaborative Partnerships for the Future of the Lab
2) The New Process to Achieve Chest Pain Accreditation
3) Hemoglobin A1c – Assuring Confidence & Efficiency in Clinical Practice
4) NT-proBNP: Analytical and Clinical Considerations for Improving Patient Care

New products featured by Roche this year include:

• cobas u 601* urine analyzer: a new, fully automated solution for urine strip testing in
  mid- to high-volume labs that delivers high-quality results through reagent test strips
  proven in 50 years of urinalysis testing.
  *Not available for sale in the U.S. A 510(k) submission is pending.
• cobas® 8100 automated workflow series: previewed at last year’s Expo, this new
  modular solution delivers automation without compromise by providing multi-level,
  bi-directional sample transport; workflow your way; and hands-free add-on/repeat
  testing. It was specifically designed to eliminate the stubborn technical barriers that
  stand in the way of true hands-off testing.
• cobas® CT/NG v2.0 Test: test for detection of Chlamydia trachomatis and Neisseria
  gonorrhoeae DNA in symptomatic and asymptomatic patients is cleared for
  use with male/female urine, self-collected (clinical setting) and cliniciancollected
  vaginal, and endocervical swab specimens, all collected in cobas PCR media,
  and cervical specimens collected in PreservCyt® solution.
• cobas® HPV Test: this fully automated, DNA-based test is the first HPV test approved
  by the FDA for first-line primary screening for cervical cancer. Approved for use with
  women 25 and older, it provides 3 results in 1 test: individual results for HPV 16 and
  18 genotypes and a pooled result for the 12 other high-risk types, all in one run, from
  one patient sample.
• Elecsys® Calcitonin immunoassay: an immunoassay for the in vitro quantitative
  determination of human calcitonin in serum and plasma.
• Elecsys® CMV IgG assay: an assay intended to be used as an aid in determining the
  serological status to CMV in individuals in which a CMV IgG test was ordered,
  including pregnant women.
• Elecsys® HBeAg immunoassay: an immunoassay for the in vitro quantitative
  determination of Hepatitis B e antigen in human serum or plasma (K2-EDTA, lithium
  or sodium heparin, and sodium citrate) in adult patients with symptoms of Hepatitis
  or at risk for Hepatitis B virus (HBV) infection.
  

Image Caption: The cobas u 601* urine analyzer